---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Advance-HTN"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Advance-HTN. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 65 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/advance-htn"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Advance-HTN

<a id="heading-3.1.2"></a>

## 3.1.2 Advance-HTN

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.1-2"></a>

#### Objective stated in the trial presentation

> “Assess the 24-hour blood pressure lowering effect of lorundrostat taken once daily in participants with uncontrolled and treatment-resistant hypertension on a standardized antihypertensive regimen”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.1-3"></a>

#### Target population stated by the company

> “The trial was designed to evaluate lorundrostat in an uncontrolled or resistant hypertensive population at the highest risk and which would normally be treated by a specialist given severity of their condition.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-03-13”
> “Primary Completion (Actual) 2025-01-15”
> “Study Completion (Actual) 2025-01-15”
> “First Posted 2023-03-15”
> “Last Update Posted 2026-01-20”
> “Completed”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.2-2"></a>

#### Number and country of locations in the ClinicalTrials.gov record

> “This study has 104 locations”
> “United States”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.2-3"></a>

#### Number of sites stated in the trial presentation

> “Multicenter (103 sites in the United States)”
> “103 Sites throughout the United States”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.2-4"></a>

#### Topline results announced in March 2025

> “RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE)”
> “today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.2.2-5"></a>

#### Presentation at the American College of Cardiology Scientific Session in March 2025

> “detailed results from Advance-HTN were presented in a late-breaking session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) on Saturday, March 29, 2025, at 1:30 p.m. CT.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.2-6"></a>

#### Publication in April 2025

> “today announced that the New England Journal of Medicine (NEJM) published the detailed results from the Company’s pivotal Phase 2 Advance-HTN trial”
> “is featured in the April 23, 2025 issue of NEJM.”

Source: [Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Official title and design in the ClinicalTrials.gov record

> “A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen”
> “The study consists of a standardized AHT regimen run-in period followed by a randomized, double-blind, placebo-controlled, parallel arm period. Following the double-blind period subjects may be offered the opportunity to participate in an open-label extension (OLE) study. Subjects electing to not participate in the OLE will undergo an end of study (EoS) visit approximately 2 weeks after the last dose of study drug to complete their participation in the study.”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.3-2"></a>

#### Design features stated in the trial presentation

> “Multicenter (103 sites in the United States)”
> “Prospective”
> “Randomized”
> “Double-blind”
> “Placebo-controlled”
> “Parallel group”
> “Phase 2b trial”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.3-3"></a>

#### Trial periods and their durations in the trial presentation

| Period | Quoted record |
| --- | --- |
| Screening | “2 weeks” |
| Single-blind run-in on the standardized regimen | “3 weeks” |
| Randomized double-blind treatment | “12 weeks” |
| After the end of treatment | “Open-label extension”; “2-week end of study visit”; “4-week washout” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Design stated in the publication abstract

> “In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.3-5"></a>

#### Role in the pivotal program stated by the company

> “today announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat in patients with confirmed uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

> “This includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial”
> “Advance-HTN evaluated the efficacy and safety of lorundrostat for the treatment of confirmed uHTN or rHTN when used as add-on therapy to a standardized, optimized, and adherent background treatment of two or three antihypertensive medications.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “At least 18 years of age at the time of signing the informed consent form”
> “At Screening: AOBP SBP of 140-180 mmHg and AOBP DBP of 65-110 mmHg, or AOBP DBP of 90-110 mmHg”
> “24-hour average ABPM SBP of 130-180 mmHg or 24-hour average ABPM DBP >80 mmHg”
> “Taking between 2 and 5 AHT medications, inclusive, at Screening visit.”
> “BMI of 18-40 kg/m2 inclusive at Screening”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “eGFR <45 mL/min/1.73 m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula”
> “Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization”
> “Serum sodium <135 mmol/L at Screening”
> “History of heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months prior to Screening.”
> “Diabetes mellitus with a glycosylated hemoglobin (HbA1c) >9% (>74.9 mmol/mol) at Screening”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.4-3"></a>

#### Age, sex, and healthy volunteers in the ClinicalTrials.gov record

> “18 Years and older”
> “Sexes Eligible for Study All”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.4-4"></a>

#### Blood pressure, medication, and laboratory thresholds in the trial presentation

| Criterion | Quoted record |
| --- | --- |
| Background antihypertensive medications at screening | “2 - 5 BP medications” |
| Office blood pressure at screening | “SBP 140 to 180 mm Hg, or DBP 90 to 110 mm Hg” |
| 24-hour ambulatory blood pressure before randomization | “SBP 130 to 180 mm Hg, or DBP > 80 mm Hg” |
| Serum sodium | “Na+ ≥ 135” |
| Estimated glomerular filtration rate | “eGFR ≥ 45” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.4-5"></a>

#### Eligibility for randomization after the standardized regimen in the publication abstract

> “Subsequently, participants with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were assigned to receive placebo”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Standardized antihypertensive regimen during the run-in

> “Switch to standardized regimen:”
> “Indapamide 2.5 mg daily or HCTZ 25 mg daily”
> “Olmesartan 40 mg daily”
> “+/- Amlodipine 10 mg daily”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.5-2"></a>

#### Standardized regimen assigned by the number of prior medications

> “Subjects who meet screening criteria had their existing hypertension medications discontinued and start on a standard regimen of an angiotensin II receptor blocker (ARB) and a diuretic, if previously on two medications, or a standard regimen of ARB, diuretic and calcium channel blocker if previously on three to five medications.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.5-3"></a>

#### Randomized treatment arms in the ClinicalTrials.gov record

| Arm | Quoted record |
| --- | --- |
| Placebo comparator | “Placebo once daily for 12 weeks” |
| Experimental: Dose 1 | “lorundrostat Dose 1 once daily for 12 weeks” |
| Experimental: Dose 2 | “lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria” |

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.5-4"></a>

#### Doses and dose-adjustment rule in the publication abstract

> “assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.5-5"></a>

#### Treatment duration and titration stated by the company

> “Subjects who remained hypertensive despite the standardized regimen were then randomized into three cohorts and treated for twelve weeks: lorundrostat 50 mg once-daily (QD), lorundrostat 50 mg QD and an option to titrate to 100 mg QD at week four based on defined criteria, or placebo.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Change in 24-hour Ambulatory Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Registered primary outcome measure in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP)” | “Baseline (Randomization) to Week 12” |

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.6.1-2"></a>

##### Primary end point defined in the publication abstract

> “The primary end point was the change in 24-hour average systolic blood pressure from baseline to week 12, assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.6.1-3"></a>

##### Ambulatory blood pressure monitoring as the reference measurement, stated by the lead investigator

> “Twenty-four-hour ambulatory blood pressure monitoring is the gold standard for assessing the true impact of an antihypertensive therapy, as it provides a more comprehensive picture of blood pressure control beyond the office setting, including overnight readings,”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.6.1-4"></a>

##### Ambulatory and clinic blood pressure as predictors of mortality

> “Ambulatory blood pressure provides a more comprehensive assessment than clinic blood pressure, and has been reported to better predict health outcomes than clinic or home pressure.”
> “After adjustment for clinic blood pressure, 24-h blood pressure remained strongly associated with all-cause deaths (HR 1·43 [95% CI 1·37-1·49]), but the association between clinic blood pressure and all-cause death was attenuated when adjusted for 24-h blood pressure (1·04 [1·00-1·09]).”
> “Ambulatory blood pressure, particularly night-time blood pressure, was more informative about the risk of all-cause death and cardiovascular death than clinic blood pressure.”

Source: [Staplin et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37156250/)

<a id="topic-3.1.2.6.1-5"></a>

##### Out-of-office blood pressure in the 2025 AHA/ACC guideline

> “both home BP and 24-hour ABPM are shown to be superior to office BP in predicting cardiovascular events.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.2.6.1-6"></a>

##### Blood pressure reduction as the basis of cardiovascular benefit

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.2.6.1-7"></a>

##### Same primary endpoint in a phase 3 trial of another aldosterone synthase inhibitor

> “The primary endpoint was change in 24 h ambulatory SBP from baseline to week 12, assessed by analysis of covariance in patients administered at least one dose of study medication with valid ambulatory SBP measurement at baseline and week 12.”

Source: [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)

<a id="topic-3.1.2.6.1-8"></a>

##### Key secondary end points in the trial presentation

> “Change in 24-hour average systolic blood pressure from baseline to week 4”
> “Proportion of participants with 24-hour average systolic blood pressure <125 mm Hg at week 4”
> “Change in 24-hour average systolic blood pressure from baseline to week 4 by obesity status”
> “Change in 24-hour average systolic blood pressure from baseline to week 4 by number of BP medications in standardized regimen”
> “Change in office systolic blood pressure from baseline to week 12 among participants escalated to 100 mg daily”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.6.1-9"></a>

##### Key secondary end point defined in the publication abstract

> “A key secondary end point was the change in 24-hour average systolic blood pressure from baseline to week 4, assessed as the placebo-adjusted change in the combined lorundrostat groups.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.6.1-10"></a>

##### Registered secondary outcome measures in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Change from baseline in 24-hour average ABPM SBP at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Baseline to Week 4” |
| “Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “at Week 4” |
| “Change from baseline in 24-hour average ABPM SBP at Week 4 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Baseline to Week 4” |
| “Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)” | “Baseline to Week 12” |
| “Change from baseline in 24-hour average ABPM SBP at Week 4, by number of AHT medications in the standardized AHT regimen (2 and 3) in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Baseline to Week 4” |
| “Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 12 in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo” | “Baseline to Week 12” |
| “Change from baseline in 24-hour average ABPM SBP at Week 12 by obesity status in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo” | “Baseline to Week 12” |
| “Change from baseline in daytime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo” | “Baseline to Week 4 and Week 12” |
| “Change from baseline in AOBP SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo” | “Baseline to Week 4 and Week 12” |
| “Change from baseline in nighttime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo” | “Baseline to Week 4 and Week 12” |
| “Change from baseline in 24-hour average ABPM SBP at Week 12, in subjects randomized to lorundrostat (pooled dosages) compared to subjects randomized to placebo” | “Baseline to Week 12” |

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 285”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants randomized and analyzed for efficacy in the trial presentation

> “285 randomized”
> “94 included in the efficacy analysis”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants in the primary and key secondary analyses stated by the company

> “50 to 100mg (n=94)”
> “50 mg (n=188, at Week 4)”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.7.1-4"></a>

##### Planned sample size and statistical power

No evidence found.

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Comparisons for the primary and key secondary end points in the publication abstract

> “assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.”
> “assessed as the placebo-adjusted change in the combined lorundrostat groups.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.7.2-2"></a>

##### Control of multiplicity for the key secondary end points

> “Controlled for multiplicity with a graphical testing approach”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Within-participant analysis for participants escalated to 100 mg

> “Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.7.2-4"></a>

##### Hyperkalemia confirmed by repeat testing in the safety analysis

> “The per-protocol procedure for validation of suspected factitious hyperkalemia specified a repeat potassium measurement within 72 hours while still taking study medication to ascertain the true incidence of hyperkalemia.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

> “Confirmed via per protocol repeat testing”
> “Spurious values (including suspected hemolysis) and values obtained following double-blind treatment period are excluded”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Screening, run-in, and randomization in the trial presentation

> “2617 patients assessed for eligibility”
> “1691 ineligible”
> “926 enrolled & started standardized regimen”
> “641 ineligible”
> “53% due to ABPM”
> “285 randomized”
> “94 included in the efficacy analysis”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.1-2"></a>

##### Randomization by treatment group in the publication abstract

> “A total of 285 participants underwent randomization; 94 were assigned to the stable-dose group, 96 to the dose-adjustment group, and 95 to the placebo group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.8.1-3"></a>

##### Participants escalated to 100 mg

> “Change in office systolic blood pressure from baseline to week 12 in participants escalated to 100 mg (n=19)”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.1-4"></a>

##### Discontinuation stated by the company

> “Lorundrostat demonstrated a favorable safety and tolerability profile in the Advance-HTN trial, with modest changes in potassium, sodium and eGFR, and a low discontinuation rate.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Participant characteristics by treatment group in the trial presentation

| Characteristic | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
| --- | --- | --- | --- |
| Age (years) | “59” | “61” | “61” |
| Women (%) | “35%” | “40%” | “44%” |
| Black or African-American (%) | “46%” | “53%” | “58%” |
| BMI (kg/m2) | “32” | “31” | “32” |
| eGFR (randomization) | “74” | “77” | “76” |
| Office BP (screening) | “155/91” | “153/88” | “152/89” |
| 24-hour ABPM (randomization) | “141/87” | “141/86” | “141/87” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.2-2"></a>

##### Age and race in the publication abstract

> “The mean age was 60 years, and 150 participants (53%) were Black.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.8.2-3"></a>

##### Obesity, sex, and race stated by the company

> “Key characteristics of participants enrolled in the Advance-HTN trial include: approximately 66% had a BMI greater than or equal to 30kg/m2, approximately 40% were women, and approximately 53% were Black or African American.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary end point: change in 24-hour average systolic blood pressure at week 12

> “After 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was -15.4 mm Hg in the stable-dose group, -13.9 mm Hg in the dose-adjustment group, and -7.4 mm Hg in the placebo group.”
> “The placebo-adjusted change in blood pressure was -7.9 mm Hg (97.5% confidence interval [CI], -13.3 to -2.6) in the stable-dose group and -6.5 mm Hg (97.5% CI, -11.8 to -1.2) in the dose-adjustment group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary end point: placebo-adjusted changes with P values in the trial presentation

> “Placebo-adjusted: -7.9 (-13.3 to -2.6) P = 0.001”
> “Placebo-adjusted: -6.5 (-11.8 to -1.2) P = 0.006”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-3"></a>

##### Key secondary end point: change in 24-hour average systolic blood pressure at week 4, combined lorundrostat groups

> “The placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 in the combined lorundrostat groups was -5.3 mm Hg (95% CI, -8.4 to -2.3).”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

> “-11.5 mmHg absolute change, -5.3 mmHg placebo-adjusted change (p<0.001)”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

| Group | Least-squares mean change at week 4 (mm Hg) |
| --- | --- |
| Placebo | “-6.2” |
| Lorundrostat 50 mg (all) | “-11.5” |
| Placebo-adjusted difference | “Placebo-adjusted: -5.3 (-8.4 to -2.3) P < 0.001” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-4"></a>

##### Key secondary end point: 24-hour average systolic blood pressure below 125 mm Hg at week 4

| Group | Proportion with 24-hour average SBP <125 mm Hg at week 4 |
| --- | --- |
| Placebo | “18%” |
| Lorundrostat 50 mg (all) | “41%” |
| Odds ratio (95% CI) | “3.3 (1.4 to 7.8) P < 0.001” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

> “41% compared to 18% on placebo (p<0.001)”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.8.3-5"></a>

##### Key secondary end point: change at week 4 by number of background medications

| Background medications | Placebo n | Placebo change (mm Hg) | Lorundrostat n | Lorundrostat change (mm Hg) | Placebo-adjusted difference |
| --- | --- | --- | --- | --- | --- |
| 2 | “n = 60” | “-5.1” | “n = 117” | “-11.2” | “-6.1 (-10.8 to -1.4) P = 0.001” |
| 3 | “n = 34” | “-7.2” | “n = 71” | “-11.8” | “-4.6 (-10.6 to 1.5) P = 0.060” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-6"></a>

##### Key secondary end point: office systolic blood pressure at week 12 in participants escalated to 100 mg

> “Change in office systolic blood pressure from baseline to week 12 in participants escalated to 100 mg (n=19)”
> “-17.5 mm Hg (-30.3 to -4.7) P < 0.001”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-7"></a>

##### Key secondary end point: relationship of body mass index to blood pressure reduction at week 4

> “Relationship of BMI to blood pressure reduction at 4 weeks”
> “No clear relationship”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-8"></a>

##### Dose escalation compared with the stable 50 mg dose

> “A dose escalation strategy from 50 to 100 mg did not lower blood pressure more than 50 mg and was associated with numerically more adverse events”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-9"></a>

##### Consistency across subgroups stated by the company

> “Lorundrostat worked equally well in those taking two baseline medications and those taking three or more, and in both men and women as well as in white and black patients.”

Source: [Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal)

<a id="topic-3.1.2.8.3-10"></a>

##### Conclusion of the publication abstract

> “Lorundrostat was associated with greater reductions in 24-hour average blood pressure than placebo in participants with uncontrolled and treatment-resistant hypertension.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Adverse events by treatment group in the trial presentation

| Adverse event | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
| --- | --- | --- | --- |
| Any serious AE | “2%” | “6%” | “8%” |
| Any study-drug related serious AE | “0” | “2%” | “1%” |
| Hypotension | “3%” | “9%” | “8%” |
| Hyponatremia | “6%” | “9%” | “11%” |
| Hyperkalemia (>6.0 mmol/L), single value | “0” | “5%” | “7%” |
| Hyperkalemia (>6.0 mmol/L), confirmed via per protocol repeat testing | “0” | “2%” | “3%” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.5-2"></a>

##### Serious adverse events stated by the company

> “In the Advance-HTN trial, there were six participants (6.4%) and eight participants (8.4%) with treatment-emergent SAEs in the lorundrostat 50 mg and lorundrostat 50 to 100 mg arms, respectively, compared to two participants (2.1%) in the placebo arm. Treatment-related SAEs occurred in 2%, 1%, and 0% of participants in the lorundrostat 50 mg, lorundrostat 50 to 100 mg, and placebo arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-3.1.2.8.5-3"></a>

##### Hyperkalemia above 6.0 mmol per liter

> “A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 5.3% and 7.4% in the 50 mg and 50 to 100 mg arms, respectively.”
> “After exclusion of the spurious results, the values for confirmed hyperkalemia were 2.1% and 3.2%, respectively.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.8.5-4"></a>

##### Hyperkalemia in Advance-HTN compared with Launch-HTN

> “The incidence of hyperkalemia (serum potassium above 6.0 mmol/L) in the 50 mg and 50mg to 100mg arms, respectively, was 1.1% and 1.5% in the Launch-HTN trial and 5.3% and 7.4% in the Advance-HTN trial.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.2.8.5-5"></a>

##### Serum electrolytes and cortisol stated by the company

> “The anticipated on-target effects on serum electrolytes, increased serum potassium and reduced serum sodium were modest and rapidly reversible upon discontinuation of lorundrostat. Suppression of cortisol production was not observed and there was a very low incidence of drug-related serious adverse events (SAEs) resulting in discontinuation or dose-adjustment of study medication.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

Advance-HTN was a 12-week phase 2 trial (the presentation calls it a “Phase 2b trial”) in 285 randomized participants at sites in the United States only (104 locations in the registry record; 103 sites in the presentation). Every participant was switched to a standardized regimen of a diuretic, olmesartan, and, for those previously on 3 to 5 drugs, amlodipine, so the results describe lorundrostat added to that regimen and may differ from its effect on top of usual background therapy; the presenters list the need for “additional data using office blood pressure on top of usual care” from Launch-HTN as a limitation. Of 926 participants who started the standardized regimen, 641 were ineligible for randomization (53% because of the ambulatory blood pressure criterion), which selects a population with confirmed uncontrolled hypertension on a standardized regimen.

The 50 to 100 mg dose-adjustment strategy produced a smaller placebo-adjusted reduction at week 12 (-6.5 mm Hg) than the stable 50 mg dose (-7.9 mm Hg), and 19 participants were escalated to 100 mg, so the trial gives limited information on the 100 mg dose. The week 4 subgroup on 3 background medications (71 lorundrostat and 34 placebo participants) had a placebo-adjusted difference of -4.6 mm Hg with a confidence interval that crossed zero (P = 0.060). The placebo group had a 24-hour systolic reduction of 7.4 mm Hg at week 12.

Single-value potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the two lorundrostat groups (2.1% and 3.2% after confirmation by repeat testing). The trial was “Not head-to-head with other classes of antihypertensive medications” and “Not a cardiovascular or kidney outcome trial”. As of November 2026 no posted results were located in the registry record, and participant disposition after randomization, discontinuations for adverse events, mean changes in potassium, sodium, and eGFR, and daytime, nighttime, and office blood pressure results by arm are not reported in the publication abstract, the presentation, the registry record, or the company releases.

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf); [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/); [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608); [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from); [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.2.9-2"></a>

#### Limitations stated in the trial presentation

> “Phase 2b trial, additional data using office blood pressure on top of usual care is anticipated from phase 3 trial (Launch-HTN)”
> “Not head-to-head with other classes of antihypertensive medications”
> “Not a cardiovascular or kidney outcome trial”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

Additional sources: [Burgos et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40802954/); [Pollock (2025)](https://pubmed.ncbi.nlm.nih.gov/40802955/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
